1. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology

2. Learning Objectives

3. The Role of the Pulmonologist in the Diagnosis and Management of Advanced NSCLC

4. National Lung Screening Trial

5. ACCP Guidelines for the Diagnosis of NSCLC

6. Multidisciplinary Approach To Diagnosis of NSCLC

7. Guidelines for Diagnosis of NSCLC

8. Role of the Pulmonologist in The Management of Lung Toxicities

9. The Role of the Pathologist in the Diagnosis and Management of Advanced Non-Small Cell Lung Cancer

10. Adequate Tissue Sampling

11. Guidelines for Molecular Testing

12. Immunotherapy and Biomarker Testing

13. Conclusions and Future Considerations

14. The Role of the Oncologist in the Management of Patients with Advanced Non-Small Cell Lung Cancer

15. Nivolumab vs Docetaxel for Advanced NSCLC

16. Immune-Related Adverse Events Associated With Nivolumab

17. KEYNOTE-001 Phase 1 Trial of Pembrolizumab for Advanced NSCLC

18. KEYNOTE-010 Phase 2/3 Trial of Pembrolizumab for Advanced NSCLC

19. Efficacy of Emerging and Combination Immunotherapies

20. The Role of the Oncology Nurse in the Management of Patients with Advanced Non-Small Cell Lung Cancer

21. The Role of the Oncology Nurse in NSCLC

23. Patient/Caregiver Education

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)